Compugen said it remains on track to report interim progression-free survival data from its MAIA-ovarian study in the first quarter of 2027. The update was part of first-quarter 2026 results and program progress across internal and partnered assets, with no major surprise or change in outlook disclosed.
Compugen said it remains on track to report interim progression-free survival data from its MAIA-ovarian study in the first quarter of 2027. The update was part of first-quarter 2026 results and program progress across internal and partnered assets, with no major surprise or change in outlook disclosed.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
